Shares of Ensysce Biosciences, Inc. (NASDAQ:ENSC – Get Free Report) dropped 5.6% during mid-day trading on Wednesday . The company traded as low as $7.73 and last traded at $8.14. Approximately 36,447 shares changed hands during trading, a decline of 93% from the average daily volume of 520,825 shares. The stock had previously closed at $8.62.
Ensysce Biosciences Trading Up 1.4 %
The stock has a market capitalization of $10.77 million, a price-to-earnings ratio of -0.30 and a beta of 0.60. The stock has a 50-day simple moving average of $8.24 and a 200 day simple moving average of $6.63.
Ensysce Biosciences (NASDAQ:ENSC – Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported $1.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.50) by $5.55. Ensysce Biosciences had a negative return on equity of 292.81% and a negative net margin of 179.26%. The firm had revenue of $3.42 million during the quarter, compared to analysts’ expectations of $0.25 million. Sell-side analysts expect that Ensysce Biosciences, Inc. will post -12.44 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
About Ensysce Biosciences
Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.
Featured Articles
- Five stocks we like better than Ensysce Biosciences
- How to Evaluate a Stock Before BuyingÂ
- Constellation Energy: Stock Climbs on Billion-Dollar Contract
- Insider Trades May Not Tell You What You Think
- Vistra Stock: Powered for Continued Gains in the New Year
- 5 Top Rated Dividend Stocks to Consider
- These 3 AI Stocks Are Ready to Lead in 2025
Receive News & Ratings for Ensysce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ensysce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.